We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-0.86%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.19B
AUM Growth
-$288M
Cap. Flow
-$155M
Cap. Flow %
-13.04%
Top 10 Hldgs %
42.35%
Holding
170
New
36
Increased
27
Reduced
26
Closed
54

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$49M
2
LLY icon
Eli Lilly
LLY
+$41.1M
3
ABBV icon
AbbVie
ABBV
+$26.3M
4
PANW icon
Palo Alto Networks
PANW
+$13.1M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$11.8M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$60.1M
2
JNJ icon
Johnson & Johnson
JNJ
+$28.4M
3
GNRC icon
Generac Holdings
GNRC
+$14.3M
4
LPSN icon
LivePerson
LPSN
+$14.2M
5
AMZN icon
Amazon
AMZN
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 63.14%
2 Technology 10.82%
3 Industrials 3.99%
4 Financials 3.13%
5 Communication Services 1.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPIX
76
DELISTED
ESSA Pharma
EPIX
$3.75M 0.32%
469,402
-178,901
-28% -$2.84M
DYN icon
77
Dyne Therapeutics
DYN
$4.7B
$3.65M 0.31%
225,083
-144,631
-39% -$2.56M
IMUX icon
78
Immunic
IMUX
$190M
$3.45M 0.29%
+38,981
New +$3.84M
EUCR
79
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
$3.22M 0.27%
329,025
– –
QURE icon
80
CALL
uniQure
QURE
$3.03B
$3.2M 0.27%
+100,000
New +$3.05M
NTLA icon
81
Intellia Therapeutics
NTLA
$1.49B
$3.17M 0.27%
23,647
-28,903
-55% -$4.38M
LESL icon
82
Leslie's
LESL
$8.9M
$3.08M 0.26%
+7,500
New +$3.59M
OTMO
83
DELISTED
Otonomo Technologies Ltd. Ordinary shares
OTMO
$2.87M 0.24%
+40,000
New +$3.8M
ARGX icon
84
argenx
ARGX
$53.4B
$2.79M 0.23%
9,249
– –
DICE
85
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$2.78M 0.23%
+85,000
New +$2.89M
BGMS
86
Bio Green Med Solution Inc
BGMS
$4.91M
$2.68M 0.23%
141
– –
GLUE icon
87
Monte Rosa Therapeutics
GLUE
$1.4B
$2.67M 0.22%
119,647
+19,647
+20% +$563K
HIPO icon
88
Hippo Holdings
HIPO
$830M
$2.64M 0.22%
+22,599
New +$3.96M
RPTX
89
DELISTED
Repare Therapeutics
RPTX
$2.63M 0.22%
100,391
– –
CVRX icon
90
CVRx
CVRX
$137M
$2.48M 0.21%
150,000
– –
CYT
91
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$2.37M 0.2%
135,145
+10,145
+8% +$190K
ANNX icon
92
Annexon
ANNX
$834M
$2.3M 0.19%
123,637
-24,681
-17% -$501K
TMPM
93
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$2.15M 0.18%
219,440
– –
ARYE
94
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$1.98M 0.17%
+200,000
New +$1.99M
JYAC
95
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$1.95M 0.16%
199,028
– –
ACHL
96
DELISTED
Achilles Therapeutics
ACHL
$1.89M 0.16%
242,500
-49,694
-17% -$327K
AMAT icon
97
Applied Materials
AMAT
$403B
$1.87M 0.16%
+14,500
New +$1.97M
MOLN
98
Molecular Partners
MOLN
$1.58M 0.13%
+80,555
New +$1.58M
ERAS icon
99
Erasca
ERAS
$6.3B
$1.49M 0.12%
+70,000
New +$1.44M
LVTX
100
DELISTED
LAVA Therapeutics
LVTX
$1.27M 0.11%
215,359
– –
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2021 Portfolio in Review

As of Q3 2021, Sphera Funds Management held 170 positions worth $1.19B, down 19% from $1.48B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Sphera Funds Management withdrew a net $155M in Q3 2021, closing 54 positions and reducing 26 holdings. Its most notable exit was Merck, an estimated $60.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 55% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Pfizer worth $47.6M.

  • Sphera Funds Management's largest Q3 2021 buy was Pfizer: 1,106,528 shares worth $47.6M.
  • Sphera Funds Management added most to Eli Lilly in Q3 2021, an estimated $41.1M increase.
  • Sphera Funds Management's biggest Q3 2021 reduction was Johnson & Johnson, cutting an estimated $28.4M.
  • Sphera Funds Management fully exited Merck in Q3 2021, selling an estimated $60.1M.
  • Sphera Funds Management's ten largest holdings make up 42% of its $1.19B portfolio in Q3 2021.
  • Sphera Funds Management opened 36 new positions and closed 54 in Q3 2021.
  • Sphera Funds Management's portfolio value fell 19% quarter-over-quarter to $1.19B.

Based on Sphera Funds Management's 13F filing for Q3 2021, filed 15 Nov 2021.